TARO-DOCETAXEL SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

DOCETAXEL

可用日期:

TARO PHARMACEUTICALS INC

ATC代码:

L01CD02

INN（国际名称）:

DOCETAXEL

剂量:

80MG

药物剂型:

SOLUTION

组成:

DOCETAXEL 80MG

给药途径:

INTRAVENOUS

每包单位数:

100

处方类型:

Prescription

治疗领域:

ANTINEOPLASTIC AGENTS

產品總結:

Active ingredient group (AIG) number: 0127884004; AHFS:

授权状态:

CANCELLED PRE MARKET

授权日期:

2022-07-11

产品特点

_ _
_Pr_
_Taro-Docetaxel - Product Monograph _
_ _
_Page 1 of 57 _
PRODUCT MONOGRAPH
PR
TARO-DOCETAXEL
(Docetaxel for Injection)
Single Vial Formulation
CONCENTRATED SOLUTION
20 MG / ML
80 MG / 4 ML
160 MG / 8 ML
USP Standard
FOR INTRAVENOUS INFUSION, MUST BE DILUTED BEFORE USE
ANTINEOPLASTIC AGENT
Taro Pharmaceuticals Inc.
Date of Revision:
130 East Drive, Brampton August 10, 2021
Ontario L6T 1C1
Submission Control No: 253784
_ _
_Pr_
_Taro-Docetaxel - Product Monograph _
_ _
_Page 2 of 57 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
..................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................27
DOSAGE AND ADMINISTRATION
..............................................................................28
OVERDOSAGE
................................................................................................................31
ACTION AND CLINICAL PHARMACOLOGY
............................................................32
STORAGE AND STABILITY
..........................................................................................33
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................34
PART II: SCIENTIFIC INFORMATION
....................................................................35
PHARMACEUTICAL INFORMATION
..........................................................................35
CLINICAL TRIALS
.............................................................